Dr. Lal Pathlabs Ltd. News and Updates

Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Dr. Lal Pathlabs Ltd. from all sources in a single place.

Load latest

Dr. Lal Pathlabs Ltd.

10 Nov 2020

2893.80

1.45%

Dr Lal PathLabs, Thyrocare slip on profit booking on Covid vaccine optimism

Business Standard

From March lows, the stock price of Thyrocare Technologies has been more-than-tripled and of Dr Lal PathLabs more-than-doubled on the BSE

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.

Dr. Lal Pathlabs Ltd.

06 Nov 2020, 03:20PM

2893.80

1.45%

Dr Lal PathLabs' Q2 net profit rises 6%, revenue up 18% YoY

Moneycontrol

Consolidated revenue for the said quarter came at Rs 431.9 crore, up 18 percent YoY from Rs 365.6 crore in the corresponding quarter of the previous financial year.

Dr. Lal Pathlabs Ltd. is trading below its 200 day SMA of 2975.6

Dr. Lal Pathlabs Ltd.

09 Oct 2020

2893.80

1.45%

Dr Lal PathLabs exposed data of millions of patients, including COVID-19 test results: Report

Moneycontrol

The data included patients' booking details such as their name, address, phone number, email id, payment details, digital signature, and also the type of medical tests they had taken.

Dr. Lal Pathlabs Ltd. is trading below its 200 day SMA of 2975.6

Data of millions of Dr Lal PathLabs patients exposed, including address, phone numbers, email ids

Business Today | 09 Oct 2020

Dr. Lal Pathlabs Ltd.

08 Oct 2020, 08:39AM

2893.80

1.45%

Trade Spotlight: Metropolis Healthcare, Dr Lal Pathlabs Ambuja Cement in focus

Moneycontrol

Dr Lal Pathlabs gained more than 11 percent, Metropolis Healthcare was up more than 4 percent and Ambuja Cement which hit a 52-week high closed with gains of more than 4 percent.

Dr. Lal Pathlabs Ltd. has gained 17.49% in the last 1 Month

Dr. Lal Pathlabs Ltd.

09 Aug 2020

2893.80

1.45%

Margin pressures likely to cap upside for Dr Lal Pathlabs: Analysts

Business Standard

Valuations, too, do not leave much scope for gains

Dr. Lal Pathlabs Ltd. has gained 17.49% in the last 1 Month

Dr. Lal Pathlabs Ltd.

08 Aug 2020

2893.80

1.45%

Sell Dr. Lal PathLabs; target of Rs 1006: Prabhudas Lilladher

Moneycontrol

Prabhudas Lilladher is bearish on Dr. Lal PathLabs has recommended sell rating on the stock with a target price of Rs 1006 in its research report dated August 03, 2020.

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.

Dr. Lal Pathlabs Ltd.

06 Aug 2020

2893.80

1.45%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

The company's growth in COVID business, strong brand recall, gradual unlock of cities should support growth in upcoming quarters. Given the limited upside potential we downgrade our rating to HOLD with a revised target price of Rs. 1,995 based on 53x FY22E EPS. COVID-19 tests contribute to the top line DLPL's Q1FY21 top line went down 20.6% YoY to Rs. 266cr severely impacted by COVID-19 and subsequent lock down impacting the revenue in April (-61% YoY) and May (-12% YoY), however some respite was seen in June (+14% YoY) when cities were...

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.

Dr. Lal Pathlabs Ltd.

04 Aug 2020

2893.80

1.45%

Margin pressures to cap upside for Dr Lal Pathlabs as Covid dents volumes

Business Standard

Valuations too do not leave much scope for gains

Dr. Lal Pathlabs Ltd. has an average target of 2923.50 from 4 brokers.

Dr. Lal Pathlabs Ltd.

03 Aug 2020

2893.80

1.45%

Q1FY21 Result Update - COVID test paper covers the cracks of slowdown - SELL

Sell: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

We remain negative on the entire diagnostic chain with a belief of 1) premium players losing their market share to unorganized players, 2) B2B (40% of revenue) partners negotiating to partially offset their loss of profit, 3) Inability to hike prices causing lower realization level (Revenue/Patient) and 4) higher fixed costs (60-65% of operating cost for DLPL), new compliance expense and home collection of samples will lead to lower EBITDA margin. However even after increased estimate, we maintain SELL' recommendation but revised TP to Rs1,006 (from Rs895) on PE 40x of FY22E due to challenging...